2. GPCR/G Protein Neuronal Signaling NF-κB
  3. Orexin Receptor (OX Receptor) NF-κB
  4. SHR-1806

SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer.

For research use only. We do not sell to patients.

SHR-1806

SHR-1806 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SHR-1806 Related Antibodies

Top Publications Citing Use of Products

View All Orexin Receptor (OX Receptor) Isoform Specific Products:

View All Isoforms
OX2 Receptor OX1 Receptor

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector T cells, suppresses regulatory T cells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer[1][2].

Species Reactivity

Human
In Vitro

SHR-1806 (0.1-10000 ng/mL) binds specifically and potently to human and rhesus monkey OX40 in an ELISA format, with comparable EC50 values of 61.47 ng/mL and 60.80 ng/mL, respectively[1].
SHR-1806 (0.0001-100 nM; 1 h) exhibits potent, specific binding to OX40-expressing CHOK1-hOX40 cells and activated human T cells, with EC50 values of 1.99 nM and 0.20 nM, respectively, and no binding to activated mouse or rat T cells[1].
SHR-1806 (0.01-100 nM; 1 h) potently blocks the interaction between OX40 and OX40L in CHOK1-hOX40L cells, with an IC50 of 12.51 nM[1].
SHR-1806 (0.01-100 nM; 5 h) potently activates NF-κB signaling in Jurkat-NF-κB-Luc-hOX40 cells co-cultured with Raji cells, with an EC50 of 0.36 nM, demonstrating greater potency than GPX4[1].
SHR-1806 (1-1000 ng/mL; 72 h) potently activates human memory CD4+ T cells to secrete IFN-γ, with greater activity than the reference antibody GPX4 at equivalent concentrations[1].
SHR-1806 (0.01-100 nM; 15 min) exhibits potent ADCC activity against HEK293-hOX40 cells, with an EC50 of 0.01 nM, demonstrating superior potency compared to GPX4[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SHR-1806 Related Antibodies
In Vivo

SHR-1806 (0.3-3 mg/kg; i.p.; every 3 days; 6 total doses) exhibits dose-dependent antitumor efficacy in human OX40 knock-in mice bearing MC38 tumors[1].
SHR-1806 (1 mg/kg; i.p.; every 3 days; 4 total doses) at 1 mg/kg suppresses local and distant MC38 tumor growth in human OX40 knock-in mice, and enhances intratumoral effector T cell responses, with synergistic antitumor activity when combined with a TLR7 agonist[1].
SHR-1806 (0.3-1 mg/kg; i.p.; twice weekly; 3 doses then 3 additional doses) (dose-adjusted from 0.3 to 1 mg/kg) exhibits antitumor efficacy against MC38/H-11 tumors in human OX40 knock-in mice, with enhanced activity when combined with a PD-L1 inhibitor[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Human OX40 knock-in mice (maintained under SPF conditions)[1]
Dosage: 0.3 mg/kg; 1 mg/kg; 3 mg/kg
Administration: i.p.; every 3 days; 6 total doses
Result: Demonstrated dose-dependent tumor growth inhibition with TGI values of 47.3%, 82.4%, and 90.5% at 0.3, 1, and 3 mg/kg, respectively.
Achieved a higher TGI (90.5%) than reference antibody GPX4 (78.2% TGI) at 3 mg/kg.
Increased the percentage of intratumoral CD3+ T cells, CD8+ T cells, and CD4+ T cells, and reduced the percentage of intratumoral regulatory T cells (Tregs) at 3 mg/kg compared to the control group.
Caused no significant body weight changes during treatment.
Animal Model: Human OX40 knock-in mice (maintained under SPF conditions)[1]
Dosage: 1 mg/kg
Administration: i.p.; every 3 days; 4 total doses
Result: Suppressed tumor growth in both right and left flank tumors as monotherapy.
Achieved TGI of 89.0% for right-side tumors and 83.6% for left-side tumors on Day 9 post-treatment when combined with intratumoral SHR2150 (TLR7 agonist).
Increased intratumoral CD3+ T cell infiltration and the percentage of proliferating CD3+CD8+Ki67+ T cells compared to controls as monotherapy.
Caused no significant body weight changes during treatment.
Gene ID

7293  [NCBI]

Accession
Target

TNFRSF4/OX40/CD134
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SHR-1806 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SHR-1806SHR1806SHR 1806Orexin Receptor (OX Receptor)NF-κBHypocretin ReceptorHCRT ReceptorNuclear factor-κBNuclear factor-kappaBT cellsOX40regulatory T cellsMC38 tumorsADCCinterferon-gammahuman OX40 knock-in miceCDCrhesus monkeymurine colon cancer modelsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SHR-1806
Cat. No.:
HY-P992462
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.